公开(公告)号：GR851291B

公开(公告)日：1985-11-25

申请号：GR850101291

申请日：1985-05-27

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  UHLMANN EUGEN DR ,  WENGENMAYER FRIEDRICH DR ,  MULLNER HUBERT DR ,  WINNACKER ERNST LUDWIG PROF DR ,  MERTZ ROLAND DR ,  OKAZAKI HIROSHI DR

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/16 ,  C07H21/04 ,  C07K14/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/55 ,  C12N1/20 ,  C12N15/26 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19

公开(公告)号：GR850679B

公开(公告)日：1985-07-16

申请号：GR850100679

申请日：1985-03-18

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  LEINEWEBER MICHAEL DR ,  UHAMANN EUGEN DR ,  ULMER WOLFGANG DR

IPC: C12N15/09 ,  A61K38/21 ,  C07H21/04 ,  C07K1/22 ,  C07K14/52 ,  C07K14/555 ,  C07K14/57 ,  C07K16/00 ,  C12N1/20 ,  C12P21/02 ,  C12R1/19

Abstract: A specific DNA sequence can be used in the process to obtain human gamma -interferon. The gene is advantageously synthesised in the form of several fragments which are enzymatically ligated to give larger part-sequences which are incorporated into hybrid plasmids and amplified in host organisms. The part-sequences are reisolated and then combined to give the complete gene, which is incorporated into a hybrid plasmid, and the latter is expressed in a host organism.

公开(公告)号：DE3332068A1

公开(公告)日：1985-03-21

申请号：DE3332068

申请日：1983-09-06

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  JAEGER ALFRED DR

IPC: C07H19/10 ,  C07F9/48 ,  C07H19/04 ,  C07H19/20 ,  C07H19/207 ,  C07H21/00 ,  C07H21/04 ,  C07H23/00

公开(公告)号：AT65797T

公开(公告)日：1991-08-15

申请号：AT85106279

申请日：1985-05-22

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  UHLMANN EUGEN DR ,  WENGENMAYER FRIEDRICH DR ,  MUELLNER HUBERT DR ,  WINNACKER ERNST-LUDWIG PROF DR ,  MERTZ RONALD DR ,  OKAZAKI HIROSHI DR

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/16 ,  C07H21/04 ,  C07K14/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/55 ,  C12N1/20 ,  C12N15/26 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  C07K13/00

公开(公告)号：GR852404B

公开(公告)日：1986-02-04

申请号：GR850102404

申请日：1985-10-04

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  UHLMANN EUGEN DR ,  WETEKAM WALDEMAR DR ,  KOENIG WOLFGANG DR ,  MULLNER HUBERT DR

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/04 ,  A61K38/22 ,  A61P5/00 ,  C07K14/00 ,  C07K14/575 ,  C07K14/60 ,  G01N33/74

公开(公告)号：GR852000B

公开(公告)日：1985-12-18

申请号：GR850102000

申请日：1985-08-16

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  UHLMANN EUGEN DR ,  LEINEWEBER MICHAEL DR

IPC: C12N15/09 ,  C07K14/005 ,  C07K14/195 ,  C07K14/52 ,  C07K14/555 ,  C07K14/57 ,  C12N1/20 ,  C12N15/00 ,  C12N15/72 ,  C12P19/34 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19

Abstract: 1. Claims (for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL and SE) A synthetic regulation region for the expression of heterologous genes in E. coli, containing a promotor, a modified lac operator and a ribosome-binding site, characterized in that a) the -35 region in the promotor has the nucleotide sequence (coding strand) TTGACAT or CTTGACAT b) the -10 region in the promotor has the nucleotide sequence (coding strand) GTATAAT, c) a spacer group of 14 to 17 base-pairs is between the -35 and the -10 regions, and d) a spacer group of 6 to 14 base-pairs is located between the ribosome-binding site and the ATG start codon. 1. Claims (for the Contracting State AT) A process for the expression of heterologous genes in E. coli, characterized by placing, upstream of the heterologous gene in the direction of reading, a synthetic regulation region which contains a promotor, a modified lac operator and a ribosome-binding site, in which a) the -35 region in the promotor has the nucleotide sequence (coding strand) TTGACAT or CTTGACAT b) the -10 region in the promotor has the nucleotide sequence (coding strand) GTATAAT, c) a spacer group of 14 to 17 base-pairs is between the -35 and the -10 regions, and d) a spacer group of 6 to 14 base-pairs is located between the ribosome-binding site and the ATG start codon.

公开(公告)号：DE3328793A1

公开(公告)日：1985-02-28

申请号：DE3328793

申请日：1983-08-10

Applicant: HOECHST AG

Inventor： KOENIG WOLFGANG DR ,  ENGELS JOACHIM DR ,  UHLMANN EUGEN DR ,  WETEKAM WALDEMAR DR

IPC: C12N15/09 ,  A61K38/22 ,  C07H21/04 ,  C07K14/005 ,  C07K14/195 ,  C07K14/575 ,  C07K14/645 ,  C07K19/00 ,  C12N1/20 ,  C12N15/00 ,  C12N15/62 ,  C12P21/02 ,  C12R1/19 ,  C07C103/52 ,  C12P19/34 ,  A61K37/24

Abstract: Secretin, which cannot be prepared directly by genetic engineering because of its carboxylic acid carboxyl-terminus, can be obtained by preparing secretylglycine by genetic engineering and then obtaining secretin therefrom by enzymatic conversion of the terminal glycine radical. The gene for the secretylglycine is synthesized chemically from smaller single-stranded units which are linked enzymatically to give the complete gene, incorporated into a suitable vector and amplified therein, after which the peptide is isolated directly or as a fusion protein and, after cyanogen bromide cleavage, is converted enzymatically into secretin.

公开(公告)号：AT40717T

公开(公告)日：1989-02-15

申请号：AT84109276

申请日：1984-08-04

Applicant: HOECHST AG

Inventor： KOENIG WOLFGANG DR ,  ENGELS JOACHIM DR ,  UHLMANN EUGEN DR ,  WETEKAM WALDEMAR DR

IPC: C12N15/09 ,  A61K38/22 ,  C07H21/04 ,  C07K14/005 ,  C07K14/195 ,  C07K14/575 ,  C07K14/645 ,  C07K19/00 ,  C12N1/20 ,  C12N15/00 ,  C12N15/62 ,  C12P21/02 ,  C12R1/19 ,  C07K7/32 ,  C07K13/00

公开(公告)号：DE3429430A1

公开(公告)日：1986-02-20

申请号：DE3429430

申请日：1984-08-10

Applicant: HOECHST AG

Inventor： BRAUER DIETER DR ,  ENGELS JOACHIM DR ,  HABERMANN PAUL DR ,  UHLMANN EUGEN DR ,  WENGENMAYER FRIEDRICH DR

IPC: C12N15/09 ,  A61K38/00 ,  C07H21/00 ,  C07H21/04 ,  C07K14/00 ,  C07K14/435 ,  C07K14/815 ,  C12N1/20 ,  C12N15/00 ,  C12N15/62 ,  C12N15/72 ,  C12P19/34 ,  C12P21/02 ,  C12R1/19 ,  C12P21/00 ,  A61K37/02 ,  A61K37/48

Abstract: Hirudin can be obtained using a specific DNA sequence in a genetic engineering process. The gene is advantageously synthesised in the form of several fragments which are enzymatically ligated to give two larger part-sequences which are incorporated into hybrid plasmids and amplified in host organisms. The part-sequences are reisolated and then combined to form the complete gene which is incorporated into a hybrid plasmid and the latter is expressed in a host organism.

公开(公告)号：DE3414831A1

公开(公告)日：1985-10-31

申请号：DE3414831

申请日：1984-04-19

Applicant: HOECHST AG

Inventor： ENGELS JOACHIM DR ,  LEINEWEBER MICHAEL DR ,  UHLMANN EUGEN DR ,  ULMER WOLFGANG DR

IPC: A61K38/21 ,  A61K38/00 ,  C07H21/04 ,  C07K1/22 ,  C07K14/52 ,  C07K14/555 ,  C07K14/57 ,  C07K16/00 ,  C12N1/20 ,  C12N1/21 ,  C12N15/00 ,  C12N15/09 ,  C12P19/34 ,  C12P21/02 ,  C12R1/19 ,  C12N1/00 ,  A61K45/02

Abstract: Partial sequences of human- gamma -interferon, comprising aminoacid sequences 5 to 127, 1 to 127 and 5 to 146, having biological activity. These partial sequences can be obtained by a genetic engineering process, for which purpose the appropriate DNA sequences are chemically synthesized. The DNA sequences are incorporated in hybrid plasmids, and the latter are introduced into host organisms and their expression is induced there. The biologically active polypeptides are suitable, as is human- gamma -interferon, for medicaments.